Pan-Cancer Drivers Are Recurrent Transcriptional Regulatory Heterogeneities in Early-Stage Luminal Breast Cancer

被引:8
|
作者
Singh, Shambhavi [1 ]
Sutcliffe, Matthew D. [1 ]
Repich, Kathy [2 ]
Atkins, Kristen A. [3 ]
Harvey, Jennifer A. [2 ,4 ]
Janes, Kevin A. [1 ,5 ]
机构
[1] Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22908 USA
[2] Univ Virginia, Dept Radiol, Charlottesville, VA 22908 USA
[3] Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA
[4] Univ Rochester, Med Ctr, Dept Imaging Sci, Rochester, NY 14642 USA
[5] Univ Virginia, Biochem & Mol Genet, Charlottesville, VA 22908 USA
关键词
SINGLE-CELL; GENE-EXPRESSION; EPITHELIAL-CELLS; TUMOR; PROGRAMS; TISSUES; SMART-SEQ2; CYCLE; RISK; P53;
D O I
10.1158/0008-5472.CAN-20-1034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The heterogeneous composition of solid tumors is known to impact disease progression and response to therapy. Malignant cells coexist in different regulatory states that can be accessed transcrip-tomically by single-cell RNA sequencing, but these methods have many caveats related to sensitivity, noise, and sample handling. We revised a statistical fluctuation analysis called stochastic profiling to combine with 10-cell RNA sequencing, which was designed for laser-capture microdissection (LCM) and extended here for immuno-LCM. When applied to a cohort of late-onset, early-stage luminal breast cancers, the integrated approach identified thousands of candidate regulatory heterogeneities. Intersecting the candidates from different tumors yielded a relatively stable set of 710 recurrent heterogeneously expressed genes (RHEG), which were significantly variable in >50% of patients. RHEGs were not strongly confounded by dissociation artifacts, cell-cycle oscillations, or driving mutations for breast cancer. Rather, RHEGs were enriched for epithelial-to-mesenchymal transition genes and, unexpectedly, the latest pan-cancer assembly of driver genes across cancer types other than breast. These findings indicate that heterogeneous transcriptional regulation conceivably provides a faster, reversible mechanism for malignant cells to evaluate the effects of potential oncogenes or tumor suppressors on cancer hallmarks. Significance Profiling intratumor heterogeneity of luminal breast carcinoma cells identifies a recurrent set of genes, suggesting sporadic activation of pathways known to drive other types of cancer.
引用
收藏
页码:1840 / 1852
页数:13
相关论文
共 50 条
  • [31] Denosumab in early-stage breast cancer reply
    Gnant, Michael
    Pfeiler, Georg
    Frantal, Sophie
    LANCET ONCOLOGY, 2019, 20 (05): : E236 - E236
  • [32] Trastuzumab (Herceptin) for early-stage breast cancer
    Ismael, Gustavo
    Rosa, Daniela Dornelles
    de Azambuja, Evandro
    Braga, Sofia
    Piccart-Gebhart, Martine
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (02) : 239 - +
  • [33] The quality of early-stage breast cancer care
    Bickell, NA
    Aufses, AH
    Chassin, MR
    ANNALS OF SURGERY, 2000, 232 (02) : 220 - 224
  • [34] Controversies in Pathology in Early-Stage Breast Cancer
    Goldstein, S. Neal
    SEMINARS IN RADIATION ONCOLOGY, 2011, 21 (01) : 20 - 25
  • [35] Drug therapy in early-stage breast cancer
    Hara, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S1306 - S1306
  • [36] Improving Outcomes in Early-Stage Breast Cancer
    Glueck, Stefan
    Mamounas, Terry
    Klem, Jennifer
    ONCOLOGY-NEW YORK, 2010, 24 (11): : 5 - 15
  • [37] Adjuvant bisphosphonates for early-stage breast cancer
    Brufsky, Adam
    LANCET ONCOLOGY, 2011, 12 (07): : 610 - 611
  • [38] TREATMENT OF EARLY-STAGE BREAST-CANCER
    HALL, WH
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (03): : 391 - 395
  • [39] Pan-cancer onco-signatures reveal a novel mitochondrial subtype of luminal breast cancer with specific regulators
    Ines Simeone
    Michele Ceccarelli
    Journal of Translational Medicine, 21
  • [40] Pan-cancer onco-signatures reveal a novel mitochondrial subtype of luminal breast cancer with specific regulators
    Simeone, Ines
    Ceccarelli, Michele
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)